{"url_path":"/sec/artv/8-k/2026-09-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-389308-index.html","accession_number":"0001193125-26-389308","cik":"0001817241","ticker":"ARTV","issuer_name":"Artiva Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-389308-index.html","primary_entity_key":"0001817241","primary_entity_name":"Artiva Biotherapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n(d) Exhibits\n\n \n\n \n\n \n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n10.1\n\n[Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan, as amended.](artv-ex10_1.htm)\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nArtiva Biotherapeutics, Inc.\n\n \n\n \n\nBy:\n\n/s/ Fred Aslan\n\n \n\nFred Aslan, M.D.\n\n \n\nChief Executive Officer\n\nDated: September 11, 2026"}